Amos Korczyn

Stopping clinical therapy trials because of futility: should it be allowed? 2:30
Stopping clinical therapy trials because of futility: should it be allowed?
Amos Korczyn • 9 Mar 2023
Overview of the 17th World Congress on Controversies in Neurology 3:44
Overview of the 17th World Congress on Controversies in Neurology
Amos Korczyn • 9 Mar 2023
CONy 2023: controversies in neuroimmunology, PD and AD 7:53
CONy 2023: controversies in neuroimmunology, PD and AD
Amos Korczyn • 9 Mar 2023
Stroke & epilepsy debates at CONy 2023 6:20
Stroke & epilepsy debates at CONy 2023
Amos Korczyn • 9 Mar 2023
Is α-synuclein a useful therapeutic target in Parkinson’s disease? 4:31
Is α-synuclein a useful therapeutic target in Parkinson’s disease?
Amos Korczyn • 7 Mar 2022
CONy 2021: scientific debate evolves the treatment of neurological diseases 2:33
CONy 2021: scientific debate evolves the treatment of neurological diseases
Amos Korczyn • 16 Sep 2021
Evaluating the amyloid hypothesis in Alzheimer’s disease 2:09
Evaluating the amyloid hypothesis in Alzheimer’s disease
Amos Korczyn • 16 Sep 2021
What is Alzheimer’s disease? The importance of definitions 4:47
What is Alzheimer’s disease? The importance of definitions
Amos Korczyn • 16 Sep 2021
The 15th World Congress on Controversies in Neurology: overview 2:10
The 15th World Congress on Controversies in Neurology: overview
Amos Korczyn • 16 Sep 2021
The content of VJNeurology is intended for healthcare professionals